SAbDab: The Structural Antibody Database

> Structural Summary

Therapeutic	Canakinumab
Target	IL1B
Heavy Chain	QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS
Light Chain	EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK
100% seqID Fv Structure	None
99% seqID Fv Structure	4g5z [Fvs: HL], 4g6j [Fvs: HL], 5bvj [Fvs: BA, DC, FE, HG], 5bvp [Fvs: HL]
95-98% seqID Fv Structure	None

> SAbDab Links

99% seqID Structure	4g5z [Fvs: HL]
99% seqID Structure	5bvj [Fvs: BA, DC, FE, HG]
99% seqID Structure	4g6j [Fvs: HL]
99% seqID Structure	5bvp [Fvs: HL]
There are no identical PDB matches to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Canakinumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

> 4g5z: H/L

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	101	102	103	104	105	106	107	108	109	110	111	112	113
canakinumab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S
4g5z	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	A	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
canakinumab	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K
4g5z	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K

> 5bvj: B/A

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	101	102	103	104	105	106	107	108	109	110	111	112	113
canakinumab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S
5bvj	E	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
canakinumab	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K
5bvj	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K

> 4g6j: H/L

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	101	102	103	104	105	106	107	108	109	110	111	112	113
canakinumab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S
4g6j	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	A	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
canakinumab	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K
4g6j	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K

> 5bvp: H/L

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	101	102	103	104	105	106	107	108	109	110	111	112	113
canakinumab	Q	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S
5bvp	E	V	Q	L	V	E	S	G	G	G	V	V	Q	P	G	R	S	L	R	L	S	C	A	A	S	G	F	T	F	S	V	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	I	I	W	Y	D	G	D	N	Q	Y	Y	A	D	S	V	K	G	R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q	M	N	G	L	R	A	E	D	T	A	V	Y	Y	C	A	R	D	L	R	T	G	P	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
canakinumab	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K
5bvp	E	I	V	L	T	Q	S	P	D	F	Q	S	V	T	P	K	E	K	V	T	I	T	C	R	A	S	Q	S	I	G	S	S	L	H	W	Y	Q	Q	K	P	D	Q	S	P	K	L	L	I	K	Y	A	S	Q	S	F	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	N	S	L	E	A	E	D	A	A	A	Y	Y	C	H	Q	S	S	S	L	P	F	T	F	G	P	G	T	K	V	D	I	K

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

> Metadata

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (August '23)	Approved
Estimated Status (August '23)	Active
Recorded Developmental Technology	Medarex UltiMAb Mouse
INN Year Proposed	2007
INN Year Recommended	2008
Companies Involved	Charite - Universitatsmedizin Berlin, Novartis, Triemli hospital, University Hospital Tubingen, University Hospital Zurich
Conditions Approved	Adult-onset Still's disease, Cryopyrin-associated periodic syndromes, Familial autosomal dominant periodic fever, Familial Mediterranean fever, Gouty arthritis, Juvenile rheumatoid arthritis, Peroxisomal disorders
Conditions Active	Cardiovascular disorders, Behcet's syndrome, Non-small cell lung cancer, Abdominal aortic aneurysm, Atherosclerosis, Malignant melanoma, Osteoarthritis, Peripheral arterial occlusive disorders, Pulmonary sarcoidosis, Schnitzler syndrome, Sickle cell anaemia, Breast cancer, Pancreatic cancer, Renal cell carcinoma
Conditions Discontinued	Chronic obstructive pulmonary disease, Asthma, Diabetic retinopathy, Polymyalgia rheumatica, Rheumatoid arthritis, Type 1 diabetes mellitus, Type 2 diabetes mellitus
Notes

Thera-SAbDab

CANAKINUMAB